HC Wainwright & Co. Reiterates Buy on Amylyx Pharmaceuticals, Maintains $34 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.6%

Neg 0% Neu 89.6% Pos 0%

HC Wainwright & Co. analyst Andrew S. Fein reiterates Amylyx Pharmaceuticals (NASDAQ:AMLX) with a Buy and maintains $34 price target.